Kyorin 1H FY18 (YE Mar'19) Results - First Glance
Key highlights Overall sales (¥50b) stayed flat as brisk uptake of Flutiform (+13% to ¥6.1b), Desalex (+200% to ¥2.8b) and Nasonex (after Merck...
345 Views
Eisai 1H FY18 (YE Mar'19) Results - First Glance
Key highlights Lenvima, Eisai’s key revenue driver, performed across regions (+43% to ¥14.3b in the US, +170% to ¥4.3b in Japan and +40% to ¥3.7b...
428 Views
Innovent Biologics IPO First-Day: Take Money off the Table
Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...
514 Views
Samsung BioLogics Update
Recent developments in Samsung Biologics Co., (207940 KS)'s business have been mixed with a negative skew. First, partner Merck & Co Inc (MRK...
523 Views
Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK) is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
686 Views